Use of Lifestyle Modifications for Management of a Patient with Severely High Total Cholesterol (> 14 mmol/L) and Triglycerides (> 40 mmol/L)
- PMID: 33763342
- PMCID: PMC7957042
- DOI: 10.15280/jlm.2021.11.1.43
Use of Lifestyle Modifications for Management of a Patient with Severely High Total Cholesterol (> 14 mmol/L) and Triglycerides (> 40 mmol/L)
Abstract
In this report, we describe a case of a 37-year old man who presented with a history of total cholesterol > 14 mmol/L and triglyceride levels > 40 mmol/L. The patient was initially thought to have familial hypercholesterolemia due to his elevated total cholesterol, by his family physician. He was prescribed evolucumab, a proprotein convertase subtilisin/ kexin type 9 inhibitor drug which has shown efficacy for lowering low-density lipoprotein-cholesterol levels, to reduce his high total cholesterol. However, in this patient, the elevated total cholesterol was likely due to hypertriglyceridemia, rather than increased low-density lipoprotein-cholesterol levels. Through this case we provide an approach for the clinical management of patients with elevated total cholesterol with underlying triglycerides ≥ 10 mmol/L. The primary intervention for management of triglycerides ≥ 10 mmol/L involves lifestyle modifications including, changes in diet, exercise, reduction in body mass index, and abstinence from alcohol consumption. Secondary intervention involves management through pharmacotherapy with fibrates and statins. Creating a plan of action with the patient, incorporating lifestyle modifications alone, the patient was able to reduce the triglycerides from an average of 44.94 mmol/L to 3.28 mmol/L.
Keywords: Cholesterol; Lifestyle; Patient care management; Triglycerides.
© 2021 Journal of Lifestyle Medicine.
Conflict of interest statement
CONFLICTS OF INTERESTS The views expressed in this article are of the authors based on current literature review, and not an official position of the institution or funder. Additionally, there are no competing interests for the authors.
Figures

References
-
- Ferrieres J, Combis MS, Verdier C, Genoux AL, Gennero I, Hamdi S, Perret B, Ruidavets JB. Big data and severe hypertriglyceridemia: prevalence in 297909 individuals. Eur Heart J. 2018;39(1 suppl):ehy566–P5389. doi: 10.1093/eurheartj/ehy566.P5389. - DOI
-
- Bijvoet SM, Bruin T, Kastelein JJ. The familial hyperchylomicronaemia syndrome. Neth J Med. 1993;42(1-2) - PubMed
-
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference VA, Graham IM, Halliday A, Landmesser U, Mihaylova B, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. doi: 10.1093/eurheartj/ehz455. - DOI - PubMed
-
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R. 2018 AHA/ ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–209. doi: 10.1016/j.jacc.2018.11.002. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources